MX2016007717A - Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso. - Google Patents

Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso.

Info

Publication number
MX2016007717A
MX2016007717A MX2016007717A MX2016007717A MX2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A MX 2016007717 A MX2016007717 A MX 2016007717A
Authority
MX
Mexico
Prior art keywords
methods
preparation
another aspect
present
cyclopentyl compound
Prior art date
Application number
MX2016007717A
Other languages
English (en)
Spanish (es)
Inventor
Wu Ke
Ambrus Gyorgy
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2016007717A publication Critical patent/MX2016007717A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2016007717A 2013-12-13 2014-12-12 Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso. MX2016007717A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915575P 2013-12-13 2013-12-13
PCT/US2014/070156 WO2015089475A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Publications (1)

Publication Number Publication Date
MX2016007717A true MX2016007717A (es) 2016-09-09

Family

ID=52282957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007717A MX2016007717A (es) 2013-12-13 2014-12-12 Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso.

Country Status (16)

Country Link
US (2) US9353079B2 (enExample)
EP (1) EP3080096A1 (enExample)
JP (2) JP2016539994A (enExample)
KR (1) KR20160097310A (enExample)
CN (1) CN105814033B (enExample)
AU (1) AU2014361794B2 (enExample)
BR (1) BR112016013594A8 (enExample)
CA (1) CA2933556A1 (enExample)
CL (2) CL2016001448A1 (enExample)
IL (2) IL245917B (enExample)
MX (1) MX2016007717A (enExample)
RU (1) RU2730520C2 (enExample)
SA (1) SA516371307B1 (enExample)
SG (2) SG11201604787SA (enExample)
UA (1) UA121108C2 (enExample)
WO (1) WO2015089475A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3658149B1 (en) 2017-07-25 2021-11-10 Allergan, Inc. Solid complex comprising (z)-7-((1r,2r,3r,5s)-2-((s,e)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide, preparation and uses thereof
WO2021152473A1 (en) * 2020-01-29 2021-08-05 Kci Licensing, Inc. Multiple fluid pathway connector with foam supports

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES416865A1 (es) * 1972-07-13 1976-03-01 Pfizer Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15.
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6602900B2 (en) * 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
ES2159734T3 (es) * 1995-05-18 2001-10-16 Allergan Sales Inc Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.

Also Published As

Publication number Publication date
SA516371307B1 (ar) 2018-10-04
SG11201604787SA (en) 2016-07-28
RU2730520C2 (ru) 2020-08-24
JP2016539994A (ja) 2016-12-22
UA121108C2 (uk) 2020-04-10
AU2014361794B2 (en) 2019-04-04
CN105814033B (zh) 2019-10-25
US20150166504A1 (en) 2015-06-18
US9353079B2 (en) 2016-05-31
KR20160097310A (ko) 2016-08-17
CL2016001448A1 (es) 2017-03-03
IL245917B (en) 2021-06-30
BR112016013594A8 (pt) 2020-05-19
BR112016013594A2 (enExample) 2017-08-08
US20170087163A1 (en) 2017-03-30
JP2020073513A (ja) 2020-05-14
EP3080096A1 (en) 2016-10-19
IL283810A (en) 2021-07-29
IL245917A0 (en) 2016-08-02
CA2933556A1 (en) 2015-06-18
SG10201709702UA (en) 2018-01-30
WO2015089475A1 (en) 2015-06-18
CN105814033A (zh) 2016-07-27
AU2014361794A1 (en) 2016-06-16
CL2019000471A1 (es) 2019-07-12

Similar Documents

Publication Publication Date Title
JOP20200011A1 (ar) مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp
EA201590748A1 (ru) Противовирусные соединения против rsv
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2012003427A1 (es) Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
CU20170077A7 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
CL2016001895A1 (es) Compuestos
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
MX382600B (es) Forma cristalina de base libre de lorlatinib.
DOP2016000253A (es) Nuevos compuestos
EP4414376A3 (en) Novel depsipeptide and uses thereof
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
UA111357C2 (uk) Аналоги епоксіейкозатриєнової кислоти, композиція на їх основі, застосування для лікування захворювань та спосіб зниження гіпертонії та нефротоксичності (варіанти)
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
AU2013408771A8 (en) Prebiotic oral care compositions containing an alkyl glycoside
MX2016007717A (es) Formas solidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y metodos para su preparacion y uso.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
GT201300225A (es) Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia